Pharma BD Deal Intelligence
GSK plc / RAPT Therapeutics, Inc.
2026 · Acquisition/Merger · $2.2B · Complete
GSK entered a definitive agreement to acquire California-based, clinical-stage RAPT Therapeutics for US$58.00 per share in cash, a total value of approximately US$2.2 billion (approximately US$1.9 billion net of cash). The lead asset ozureprubart is a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food allergens, designed for once-every-12-week dosing. GSK acquires global rights excluding Mainland China, Hong Kong, Macau and Taiwan. The acquisition completed on 3 March 2026.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal.
Key facts
- Announced Jan 20, 2026
- Closed Mar 03, 2026
- Deal value $2.2B
- Deal type Acquisition/Merger
- Therapeutic area Immunology, Respiratory
- Indications Food allergy (prophylactic protection against food allergens)
- Key assets Ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylactic protection against food allergens, dosed once every 12 weeks
- Mechanism Long-acting anti-immunoglobulin E (IgE) monoclonal antibody
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2026 deals · GSK plc deals · Immunology deals